ESR1 and breast carcinoma: This novel targeted therapeutic was approved by the Food and Drug Administration in February 2015 after experimental evidence revealed that it doubled progression-free survival in older women with advanced HER2-negative, estrogen receptor (ER)-positive (ER+) breast cancer.